Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."
Perceptions of vaccines impact consumers' purchasing decisions
Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.
AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.
Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.
Resignations stymied the Office of Pharmaceutical Quality's beginning.
After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.
AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung disease.
AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.
The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.